Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Clinical trial NCT03363373 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03363373
- Sponsor
- Y-mAbs Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-03
- Primary completion
- 2026-06-30
- Enrollment
- 122
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.